PM PM Philip Morris International Loading... : Bullish and Bearish Analyst Opinions

Philip Morris cuts its profit forecast for this fiscal year after writing down the value of its investment in its Canadian affiliate by $500 million.

Short PM on vape danger

Short PM on Zyn danger

Zyns dangerous, short PM

Barbarian Capital notes Philip Morris hitting a new intraday all-time high and questions whether the TAM expansion was already priced into models for PM, MO, and BTI.

Summarizes FDA guidance on vapes and pouches; no directional view from speaker.

Dr. Friedrich Franz tweets a WSJ report that Trump is pressuring the FDA to approve flavored vapes, which could benefit tobacco stocks MO and PM if approved.

A highly upvoted comment from a self-proclaimed physician advocates for the benefits of nicotine and buying Philip Morris calls. In a stressful macro environment, "vice" stocks like tobacco often show resilience and steady cash flows. Long PM calls as a defensive, consumer-staple play during market turbulence. Regulatory crackdowns on tobacco/nicotine products or general market beta dragging the stock down.

"By 2030, we should have a total of the revenues coming from this product [smoke-free]." Additionally, "IQOS today's revenue is larger than Marlboro" and Zyn shipments are predicted to hit 1 billion in 2026. PMI has successfully executed a "self-disruption" strategy. By acquiring Swedish Match (Zyn) and developing IQOS, they have immunized themselves against the secular decline of smoking. They are capturing a new demographic (white-collar workers) who would never smoke cigarettes but will use discreet pouches. The construction of the Colorado facility indicates massive demand and a move to secure US market share against competitors like Altria. Long PM as the clear winner in the "Nicotine 2.0" transition, offering growth (Zyn) and stability (legacy pricing power) with a valuation that may re-rate higher as it becomes less of a "sin stock" and more of a consumer packaged goods (CPG) play. Regulatory crackdown on flavored pouches (similar to vaping bans); long-term health studies revealing cardiovascular risks associated with high-concentration nicotine pouches.

Olczak states that 40% of Philip Morris International's revenue is now "smoke-free" (IQOS and Zyn). He projects Zyn shipments to more than double from 421 million cans in 2023 to over 1 billion in 2026. The market historically discounts tobacco for terminal decline in combustibles. However, PM is successfully transitioning to a growth multiple business (Oral Nicotine/Heat-not-Burn). If Zyn volumes double, revenue quality improves, warranting a re-rating from "value trap" to "growth staple." Long PM as the clear winner in the nicotine transition, specifically for its ownership of Zyn (US growth engine) and IQOS (International scale). Regulatory crackdowns on flavored pouches; potential long-term health studies linking pouches to cardiovascular issues.

Investors are fleeing asset-light businesses due to AI disruption fears. Brown identifies "HALO" stocks (Heavy Assets, Low Obsolescence) as the new leadership. An LLM cannot replicate a physical bag of Fritos (Pepsi), refine gasoline (Valero), or pour concrete (Martin Marietta). These companies have "moats of physics" that AI cannot cross. LONG. These sectors (Energy, Industrials, Staples) are seeing massive inflows as "refugees" from the SaaS crash seek safety in non-disruptible cash flows. Some names (like KO) are becoming technically overbought (RSI 85+), suggesting a short-term pullback is likely within a longer uptrend.